Streetbeat News

Earnings

APRE

Aprea Therapeutics (NASDAQ:APRE) reported Q4 earnings with an EPS of $-0.92, missing estimates by -19.0% and a revenue increase of $14 thousand from the previous year. Last quarter, the company beat EPS estimates which was followed by a 5.0% drop in share price.

Portfolio Pulse from Benzinga Insights

March 26, 2024 | 1:10 pm

GANX

Gain Therapeutics (NASDAQ:GANX) reported Q4 earnings, beating estimates with an EPS of $-0.29 against an expected $-0.32. However, revenue remained unchanged from the previous year. The company had previously seen a 4.0% share price increase following last quarter's earnings beat.

Portfolio Pulse from Benzinga Insights

March 26, 2024 | 1:10 pm

PRAX

Praxis Precision Medicines' stock price increased following the announcement of positive results from a Phase 2a proof of concept study for PRAX-628, aimed at treating epilepsy patients with PPR.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 1:09 pm

NET

Cloudflare, Inc. (NYSE:NET) announced a 174% increase in channel revenue over the last two years, earning a 5-Star ranking from CRN for its Partner Program. The Cloudflare PowerUP Partner Program aims to provide clear revenue paths for global partners, emphasizing the importance of partnerships in delivering comprehensive cybersecurity solutions across various sectors. Cloudflare's connectivity cloud supports organizations in managing cyber risks, reducing costs, and fostering innovation across cloud environments.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 1:08 pm

BLUE

NBSE

OPGN

STOK

In Tuesday's pre-market session, health care stocks showed significant movement. Stoke Therapeutics and OpGen were among the top gainers, with stocks soaring by 80.2% and 77.6% respectively, following their Q4 earnings reports. ABVC BioPharma, Mesoblast, Praxis Precision Medicine, and Sutro Biopharma also saw notable increases. On the downside, NeuBase Therapeutics led the losers, dropping by 55%, followed by Tivic Health Systems, bluebird bio, BioLine Rx, iSpecimen, and IMAC Holdings, all experiencing declines post their Q4 earnings announcements.

Portfolio Pulse from Benzinga Insights

March 26, 2024 | 1:05 pm

PSNL

Personalis, Inc. (NASDAQ:PSNL) announced the validation of its NeXT Personal test, an ultra-sensitive assay for detecting minimal residual disease (MRD) and monitoring cancer treatment response. The test, which uses a personalized tumor-informed approach, demonstrated high analytical sensitivity and accuracy across nine cancer types in a study. Initial findings at the ESMO Congress showed its potential clinical benefit in early-stage lung cancer detection and outcome prediction.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 1:05 pm

KIQ

Kelso Technologies Inc. reported a fiscal year 2023 EPS of $(0.04), compared to $(0.02) in the previous year, with revenue slightly decreasing to $10.82M from $10.93M. The company experienced a decrease in gross profit and working capital, alongside a reduction in total and net assets. Adjusted EBITDA also moved to a larger loss of $(845,487) from $(83,575) in 2022. Despite these challenges, Kelso maintains a position with no interest-bearing long-term liabilities or debt.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 1:04 pm

MGM

MGM Resorts Intl (NYSE:MGM) has received mixed analyst ratings over the past quarter, with a recent shift towards more bullish views. The average 12-month price target for MGM is now $55.29, marking an 8.41% increase from the previous target of $51.00. Analysts from firms including Mizuho, Morgan Stanley, JMP Securities, Macquarie, JP Morgan, and Barclays have updated their ratings and price targets, reflecting various adjustments based on MGM's market performance and financial health. MGM's financial indicators show strong revenue growth, net margin, ROE, and ROA, but a high debt-to-equity ratio suggests financial risk.

Portfolio Pulse from Benzinga Insights

March 26, 2024 | 1:00 pm

CSR

Analysts have mixed views on Center (NYSE:CSR), with recent evaluations showing a shift towards a more neutral stance. The average 12-month price target is $62.00, indicating a 4.5% increase from the previous target. Center, a REIT focusing on apartment communities, faces challenges with a -5.57% revenue decline and a net margin of -15.24%, but has a strong ROE of -1.55% and a prudent debt management strategy.

Portfolio Pulse from Benzinga Insights

March 26, 2024 | 1:00 pm

NDAQ

Six analysts have recently shared their diverse evaluations of Nasdaq (NASDAQ:NDAQ), ranging from bullish to bearish, with an updated 12-month price target average of $69.5, marking a 12.55% increase from the previous target. The ratings reflect a positive shift in sentiment towards NDAQ, with notable actions including price target adjustments by analysts from Goldman Sachs, Piper Sandler, Oppenheimer, Rosenblatt, UBS, and Citigroup. Nasdaq's financial performance analysis reveals a below-industry average market capitalization, a 4.11% revenue growth rate over three months, a net margin of 11.96%, an exceptional ROE of 2.28%, a below-average ROA of 0.7%, and a high debt-to-equity ratio of 1.01.

Portfolio Pulse from Benzinga Insights

March 26, 2024 | 1:00 pm